Intel Pushes PC Makers Toward 18A Chips as AI Demand Surges Margin Boost Potential Fed Chair Powell Vows Not to Be a Shadow Chair as Potential Clash with Warsh Looms Silicon Valley Turns to Mundane Businesses AI and Dealmaking Reshape Accounting Property Management AI Adoption Pressures McKinsey BCG and Bain to Transform Pricing Models US Consumer Sentiment Sinks to Record Low in May as Iran Conflict Fuels Inflation Fears Surge in LongDated Treasury Yields Prompts Bond Investors to Rethink RiskFree Assumptions BODI Q1 2026 Earnings Massive EPS Beat Masks Lingering Concerns as Stock Declines CLDX Q1 2026 Earnings Slight EPS Miss as DevelopmentStage Biotech Continues NoRevenue Phase TWFG Q1 2026 Earnings Strong EPS Beat Drives Investor Attention Despite Slight Stock Decline Disc Medicine Q1 2026 Earnings NarrowerThanExpected Loss Offsets Lack of Revenue Stock Edges Down MNSO Q4 2025 Earnings Strong EPS Beat Amidst Operational Progress CompX International Inc CIX Q1 2026 Earnings Solid EPS Performance Amid Market Uncertainty CMSD Edges Higher Amid Steady Income Demand Technical Levels in Focus Ferrari NV RACE Shows Subtle Weakness as It Holds Near 348 Amid Tight Trading Abony Acquisition Corp I Units Edge Lower as SPAC Units Trade Near Par Value Oaktree Acquisition Corp III Life Sciences Unit OACCU Holds Steady at 1069 as Trading Remains Quiet Manhattan Bridge Capital LOAN Slips 118 Amid Consolidation Near Support Saga Communications SGA Q1 2026 Earnings Broadcast Loss Widens Amid Ad Market Pressure Regional Management Corp Q1 2026 Earnings Profit Beats Estimates as Stock Gains 201 DRTS Q1 2026 Earnings WiderthanExpected Loss as PreRevenue Company Continues Clinical Development IHT Q1 2026 Earnings Modest Loss Reflects Challenging Start to Fiscal Year BBGI Q4 2025 Earnings Deep Loss of 695 Per Share Stock Gains 331 TWFG Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency Morgan Stanley Lifts Devon Energy Price Target by 7 Signaling Confidence in EP Sector CRIS Q1 2026 Earnings Significant EPS Miss as Company Reports No Revenue Jazz Pharmaceuticals JAZZ Modestly Advances as Traders Eye Key Resistance Zone